Overview

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Genentech, Inc.
Valhalla Charitable Foundation

Treatments:

Ocrelizumab